AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23750422
Drug: Special effect
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special effect San Xiao decoction (1 dose/d for 12 weeks)
Trial: 23750422
Drug: Metformin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (0.5 g/time, oral, 2 times/d)
Trial: 16872965
Drug: Conventional technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional technique (veins stripped, distended, stored in saline solution)
Trial: 12611783
Drug: BCAA (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (60 g)
Trial: 10383522
Drug: OMC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 250 mg b.d.)
Trial: 9122729
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant interferon alfa-2b (rIFN‐alpha 2b)
Trial: 17646228
Drug: IV prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV prednisolone, 60 mg for 5 days
Trial: 17646228
Drug: Oral prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone, 60 mg for 5 days
Trial: 10691224
Drug: 3‐ml lidocaine‐epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐ml lidocaine‐epinephrine test dose + 12 ml bupivacaine, 0.0625%
Trial: 10691224
Drug: 3‐ml lidocaine‐epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐ml lidocaine‐epinephrine test dose + 12 ml bupivacaine, 0.125%
Trial: 27980409
Drug: Vilazodone 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone 20-40 mg/d
Trial: 20189517
Drug: Argon plasma
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon plasma coagulation (APC) in addition to biofeedback therapy (BT)
Trial: 20189517
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care only (biofeedback therapy [BT])
Trial: 8814688
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin and etoposide (EP) combined with cranial and local radiotherapy
Trial: 8814688
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with vincristine, doxorubicin and cyclophosphamide (VAC)
Trial: 8814688
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with VAC
Trial: 8877887
Drug: Multidose nebulizer
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose nebulizer (200 x 15 microL doses of flunisolide, 250 micrograms)
Trial: 8877887
Drug: Pressurized metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized metered dose inhaler (MDI, 250 micrograms of flunisolide)
Trial: 1642345
Drug: Bupivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (20 ml, 0.25%)
Trial: 8311214
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and bupivacaine
Trial: 6134535
Drug: Pancuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.08 mg kg‐1
Trial: 6134535
Drug: Vecuronium 0.057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.057 mg kg‐1
Trial: 23486618
Drug: Ultrasound-guided (US)
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided (US) facet joint injections
Trial: 16698524
Drug: Standard skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard skin medication (placebo; control group)
Trial: 31077671
Drug: Diclofenac patch
RxNorm normalized name: diclofenac Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac patch
Trial: 9495784
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy only (Control group)
Trial: 12163429
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (placebo)
Trial: 12166709
Drug: Conical crown-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conical crown-retained dentures (CC)
Trial: 10597783
Drug: 3TC/ZDV with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3TC/ZDV with 1050 mg APV added at week 12
Trial: 10597783
Drug: APV 900
RxNorm normalized name: FOS-APV
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APV 900 mg with 3TC/ZDV
Trial: 17325296
Drug: Powdered garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered garlic supplement
Trial: 17325296
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract supplement
Trial: 11788172
Drug: Garlic tablet
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic tablet (Garlet) 800mg/day
Trial: 9547667
Drug: Cognitive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive group treatment program (CT)
Trial: 7979426
Drug: One-shot group
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-shot group (one-shot arterial infusion chemotherapy)
Trial: 7979426
Drug: RV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV group (arterial infusion chemotherapy through implantable port)
Trial: 3052974
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate
Trial: 18447941
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of sugar cane policosanols (SCP)
Trial: 17192538
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus capecitabine (lapatinib at a dose of 1250 mg per day continuously plus capecitabine at a dose of 2000 mg per square meter on days 1 through 14 of a 21-day cycle)
Trial: 17192538
Drug: Capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine alone (at a dose of 2500 mg per square meter on days 1 through 14 of a 21-day cycle)
Trial: 10914847
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg hydroxychloroquine sulfate daily (Group B)
Trial: 10914847
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg hydroxychloroquine sulfate daily (Group A)
Trial: 8980924
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 50 mg of amitriptyline (AT) daily for 6 weeks
Trial: 8980924
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 25 mg of amitriptyline (AT) daily for 6 weeks
Trial: 1419760
Drug: Oral 8-methoxypsoralen
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 8-methoxypsoralen (oral 8-MOP)
Trial: 24293632
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg bolus, followed by continuous infusion of 100 mg/h for patients >70 kg or 70 mg/h for patients <70 kg over 48 h)
Trial: 22520143
Drug: Pentavalent rotavirus
RxNorm normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent rotavirus vaccine (PRV)
Trial: 11874743
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular hypotensive medication
Trial: 16228196
Drug: Ketamine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg)
Trial: 15203290
Drug: Ethanol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.6 g/kg)
Trial: 2707917
Drug: Ibopamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (100 mg, three times a day)
Trial: 30669717
Drug: Jinghuaweikang capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinghuaweikang capsules (160 mg, three times a day) + Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Trial: 30669717
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (esomeprazole 20 mg, twice a day; pectin bismuth 200 mg, three times a day; amoxicillin 1000 mg, twice a day; clarithromycin 500 mg, twice a day)
Trial: 30669717
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (esomeprazole 20 mg, twice a day; bismuth pectin 200 mg, three times a day; amoxicillin 1000 mg, twice a day; furazolidone 100 mg, twice a day)
Trial: 29596646
Drug: OBMT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBMT therapy (bismuth, metronidazole, tetracycline with omeprazole)
Trial: 29596646
Drug: OBAC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBAC therapy (bismuth, omeprazole, amoxicillin, and clarithromycin)
Trial: 29596646
Drug: Both OBMT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both OBMT and OBAC therapies
Trial: 26498268
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioral Therapy (CBT) for 11 weeks
Trial: 23262475
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered according to the same schedule as the treatment group
Trial: 21055665
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) for 10 months
Trial: 16302041
Drug: Amodiaquine Monotherapy
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine Monotherapy (AQ)
Trial: 8515822
Drug: Scopolamine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.4 mg s.c.)
Trial: 31468714
Drug: Revefenacin 700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 700 µg
Trial: 30668840
Drug: L-glutamic acid
RxNorm normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-glutamic acid inclusion levels: 2.88%
Trial: 30668840
Drug: L-glutamic acid
RxNorm normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-glutamic acid inclusion levels: 3.08%
Trial: 30668840
Drug: L-glutamic acid
RxNorm normalized name: L-Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-glutamic acid inclusion levels: 2.68%
Trial: 26312445
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections with ropivacaine (100 mg) and ketorolac (15 mg)
Trial: 10209831
Drug: Shock energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock energy programmed at twice DFT+
Trial: 7796255
Drug: long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: long term therapy
Trial: 30021811
Drug: Higher cord
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cord blood 25OHD at birth (>31 ng/mL)
Trial: 30021811
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood 25OHD levels >31 ng/mL
Trial: 25850540
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - placebo vibratory stimulation (sham treatment).
Trial: 21899766
Drug: One-page ADR
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-page ADR information letters administered at three occasions during 2008 to all physicians and nurses in the intervention units
Trial: 16799399
Drug: rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone 4 mg daily and fenofibrate 160 mg daily (PPAR group)
Trial: 14709198
Drug: Intensive subcutaneous
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive subcutaneous insulin therapy (ISIT)
Trial: 1531044
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg intravenous dose
Trial: 6435483
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl injection
Trial: 6435483
Drug: Intramuscular fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular fentanyl injection
Trial: 14725783
Drug: Computer‐assisted multimedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer‐assisted multimedia training course for intravenous injection
Trial: 8996137
Drug: L‐PAM alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PAM alone (10 mg/m2, 15 mg/m2, 17.5 mg/m2, 20 mg/m2)
Trial: 8996137
Drug: L‐PAM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐PAM plus WBH (at various doses)
Trial: 20496730
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Xuanzhong (GB 39) combined with Chinese herbs pyrogenic dressing therapy
Trial: 10735900
Drug: G‐CSF (lenogastrim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (lenogastrim) administered after chemotherapy
Trial: 10735900
Drug: G‐CSF (lenogastrim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (lenogastrim) vs non-G‐CSF group
Trial: 8823852
Drug: SmithKline Beecham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SmithKline Beecham vaccine (Engerix‐B, 10 micrograms/dose)
Trial: 30825395
Drug: Low-frequency intervention
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency intervention (monthly SMS for 6 months)
Trial: 30423575
Drug: Naloxone (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.6 mg or 3.2 mg q70 kg IV)
Trial: 2862514
Drug: Paracervical injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical injection of vasopressin
Trial: 29608680
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion (4 hours) of piperacillin-tazobactam or ceftazidime
Trial: 29608680
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime
Trial: 29608680
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion (4 hours) of beta-lactams
Trial: 26351780
Drug: LY3023703 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3023703 (30 mg)
Trial: 26351780
Drug: LY3023703 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3023703 (15 mg)
Trial: 20129825
Drug: 2 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ng/ml GM‐CSF
Trial: 15979009
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMF) treatment for patients <65 years
Trial: 12917242
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 1 g meropenem
Trial: 12917242
Drug: 3 h
RxNorm normalized name: Type 3 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 h infusion of 1 g meropenem
Trial: 12917242
Drug: 3 h
RxNorm normalized name: Type 3 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 h infusion of 0.5 g meropenem
Trial: 10629385
Drug: Dihydroepiandrosterone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroepiandrosterone (50 mg/day)
Trial: 2178719
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel sheet containing Ofloxacin
Trial: 2178719
Drug: Ointment-impregnated gauze
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment-impregnated gauze
Trial: 7378115
Drug: Preparation C
RxNorm normalized name: other nasal preparation combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation C (1 NaF tablet with 1 mg F−)
Trial: 6427714
Drug: All preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All preparations
Trial: 2742729
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg d-amphetamine
Trial: 28690028
Drug: Piperacillin/tazobactam (PIPC/TAZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG)
Trial: 24942239
Drug: 75% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75% sucrose solution
Trial: 8974104
Drug: rhGH (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (0.15 mg.kg‐1.d‐1)
Trial: 1334821
Drug: Pravastatin (lipid-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (lipid-lowering agent)
Trial: 17563161
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (ADM)
Trial: 27694216
Drug: Dietary nitrate-rich
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary nitrate-rich beetroot juice (BR), 6.2 mmol of NO3- per shot, seven 70-ml shots consumed during the 48 hours after blood donation.
Trial: 27694216
Drug: Placebo (PL),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL), seven 70-ml shots consumed during the 48 hours after blood donation.
Trial: 20953528
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg/kg intravenous)
Trial: 16645152
Drug: Intranasal E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2/NET (175 microg/275 microg)
Trial: 18806686
Drug: Oral E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NET acetate (1 mg/0.5 mg)
Trial: 15983301
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and rosiglitazone 4 mg twice daily
Trial: 6435371
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and placebo
Trial: 15983301
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and rosiglitazone
Trial: 14613469
Drug: Glyburide-metformin tablets
RxNorm normalized name: glyburide / metformin
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide-metformin tablets
Trial: 14613469
Drug: Sulfonylurea plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea plus metformin (SU+Met)
Trial: 10877192
Drug: Fructose-1,6-diphosphate (FDP)
DrugBank: Fosfructose (DB13863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose-1,6-diphosphate (FDP) infusion (5 g, 10%)
Trial: 10877192
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (5 g)
Trial: 8855984
Drug: ondansetron only
RxNorm normalized name: Ondansetron only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron only for 5 days after chemotherapy
Trial: 8855984
Drug: anti-emetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-emetic treatment with dexamethasone
Trial: 1815521
Drug: Piroximone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroximone 25 mg orally
Trial: 1815521
Drug: Piroximone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroximone 50 mg orally
Trial: 6869204
Drug: Indapamide 5
RxNorm normalized name: indapamide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 5 mg once daily for 14 days
Trial: 7322956
Drug: Indapamide treatment
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide treatment
Trial: 20583949
Drug: Dutogliptin 400
RxNorm normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutogliptin 400 mg once daily for 5 days
Trial: 20583949
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg twice daily for 5 days